Professor Kim Tieu
Professor in Neurodegenerative Diseases
Biomedical Research - Translational & Stratified Medicine (Peninsula Schools of Medicine and Dentistry)
2016-present ║ Professor ║ Plymouth University Peninsula Schools of Medicine and Dentistry.
2013-2015 ║ Associate Professor (Reader) ║ Plymouth University Peninsula Schools of Medicine and Dentistry.
2013-present ║ Adjunct Faculty ║ University of Rochester(Rochester, New York).
2015-present ║ Visiting Professor ║ Department o fNeurology, Huashan Hospital, Fudan University (Shanghai, China).
2004-2012 ║ Assistant Professor ║ Depts. of Environmental Medicine and Neurology, University of Rochester (Rochester, New York).
2000-2004 ║ Post-doctoral fellow ║ Dept. of Neurology, Columbia University, New York.
1995-2000 ║ Ph.D ║ Neuroscience, University of Saskatchewan, Canada.
1993-2000 ║ Pharmacist ║ Saskatoon, Canada
1988-1993 ║ BSP ║ Pharmacy, University of Saskatchewan, Canada.
Fellow of the Higher Education Academy, UK
Society for Neuroscience
Society of Toxicology
Roles on external bodies
Invited Scientific Review
A) Journals: Annalsof Neurology, Brain, Cell Biology and Toxicology, Cell Death and Disease,European Journal of Pharmacology, Experimental Neurology, Journal of AppliedToxicology, Journal of Neurochemistry, Journal of Neuroscience, Journal ofParkinson’s disease, Mitochondrion, Movement Disorders, Nanomedicine, NatureCommunications, Nature Chemical Biology, Naunyn-Schmiedeberg Archives ofPharmacology, Neurobiology of Disease, Neurochemical Research,Neuropharmacology, Neuroscience, Neurotherapeutics, Neurotoxicology,Pharmacology and Therapeutics, PlosOne, Scientific Reports, ToxicologicalSciences, Toxicology.
My research interest has always been to study mechanisms of neuronal dysfunction and degeneration as seen in Parkinson’s disease (PD), with the ultimate goal of developing effective therapies for this devastating neurological disorder. The research projects in my lab focus on the following fundamental questions: 1) Is mitochondrial dysfunction pathogenic in PD? If so, can mitochondrial dynamics be targeted for PD treatment? 2) The role of genetic and environmental factors in the development and progression of PD? To address these questions, we perform rigorous biochemical, histological, functional and genetic analyses in experimental models of PD. When applicable, post-mortem human samples are also used.
Grants & contracts
1) MRC ║ £511 K (2014 - 2017) ║ PI: Kim Tieu
2) NIH ║ $740 K (2014 - 2018) ║ PI: Kim Tieu
1) NIH ║ ~ $1,6 M (2006 – 2012) ║ PI: Kim Tieu
2) NIH ║ ~ 422 K (2009 – 2012) ║ PI: Kim Tieu
3) Environmental Protection Agency (EPA) ║ ~ $8 M (2005 – 2010) ║ PI: Gunter Oberdoerster, Kim Tieu: 5% effort
4) NIH ║ $25 K (2005 – 2006) ║ PI: Kim Tieu
Key publications are highlightedJournals